Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 22.03.2021 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Pathol 1 Am J Surg Pathol 5 Ann Surg Oncol 1 BMC Cancer 6 Br J Cancer 2 Breast Cancer 2 Breast Cancer (Auckl) 4 Breast Cancer Res 8 Breast Cancer Res Treat 5 Breast J 1 Cancer 1 Cancer Cell 1 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 2 Cancer Res 5 Clin Breast Cancer 2 Clin Cancer Res 1 Eur Radiol 2 Histopathology 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Surg Oncol 1 Lancet Oncol 1 Nature 1 NPJ Breast Cancer 2 Oncogene 1 Oncology 1 PLoS Comput Biol 1 PLoS One 2 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CARNAHAN M, Pockaj B, Pizzitola V, Giurescu M, et al
   Contrast-Enhanced Mammography for Newly Diagnosed Breast Cancer in Women With Breast Augmentation: Preliminary Findings.
   AJR Am J Roentgenol. 2021 Mar 17. doi: 10.2214/AJR.20.25341.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. RIZZI SKLA, Haddad CAS, Giron PS, Figueira PVG, et al
   Exercise Protocol With Limited Shoulder Range of Motion for 15 or 30 Days After Conservative Surgery for Breast Cancer With Oncoplastic Technique: A Randomized Clinical Trial.
   Am J Clin Oncol. 2021 Mar 17. pii: 00000421-900000000-98581.
   PubMed         Abstract available
   
   

   
   Am J Pathol

3. DIELEMAN S, Aarnoutse R, Ziemons J, Kooreman L, et al
   Exploring the potential of breast microbiota as biomarker for breast cancer and therapeutic response.
   Am J Pathol. 2021 Mar 10. pii: S0002-9440(21)00100.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. DUSENBERY AC, Maniaci JL, Hillerson ND, Dill EA, et al
   MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
   Am J Surg Pathol. 2021 Jan 11. doi: 10.1097/PAS.0000000000001653.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. CYR AE, Sharma R
   Forewarned Is Forearmed: Can Better Patient Counseling Increase MRI Utilization in High-Risk Women?
   Ann Surg Oncol. 2020;27:3567-3569.
   PubMed        
   
   
6. CROWN A, Grumley J
   ASO Author Reflections: Oncoplastic Surgery Does Not Compromise Surveillance Imaging.
   Ann Surg Oncol. 2020;27:3657-3658.
   PubMed        
   
   
7. FISHER CS
   To Perform an Axillary Lymph Node Dissection or Not? That Is (Still) the Question.
   Ann Surg Oncol. 2020;27:3565-3566.
   PubMed        
   
   
8. ELDREDGE-HINDY H, Pan J, Rai SN, Reshko LB, et al
   A Phase II Trial of Once Weekly Hypofractionated Breast Irradiation for Early Stage Breast Cancer.
   Ann Surg Oncol. 2021 Mar 18. pii: 10.1245/s10434-021-09777.
   PubMed         Abstract available
   
   
9. LV M, Li J, Guo H, Wang C, et al
   Correction to: Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR).
   Ann Surg Oncol. 2021 Mar 18. pii: 10.1245/s10434-021-09841.
   PubMed        
   
   

   
   BMC Cancer

10. LIN B, Liu C, Shi E, Jin Q, et al
    MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4.
    BMC Cancer. 2021;21:275.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. WANG L, Wang Q, Xu P, Fu L, et al
    YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
    Br J Cancer. 2020;123:1000-1011.
    PubMed         Abstract available
    
    
12. BEDDOK A, Xu HP, Henry AA, Porte B, et al
    Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.
    Br J Cancer. 2020;123:905-908.
    PubMed         Abstract available
    
    
13. KALAW E, Lim M, Kutasovic JR, Sokolova A, et al
    Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
    Br J Cancer. 2020;123:1665-1672.
    PubMed         Abstract available
    
    
14. JOBARD E, Dossus L, Baglietto L, Fornili M, et al
    Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01304.
    PubMed         Abstract available
    
    
15. GRIS-OLIVER A, Ibrahim YH, Rivas MA, Garcia-Garcia C, et al
    PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01293.
    PubMed         Abstract available
    
    
16. SUGANO T, Yoshida M, Masuda M, Ono M, et al
    Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
    Br J Cancer. 2020;122:1811-1817.
    PubMed         Abstract available
    
    

    
    Breast Cancer

17. BARZGAR BAROUGH N, Sajjadian F, Jalilzadeh N, Shafaei H, et al
    Understanding breast cancer heterogeneity through non-genetic heterogeneity.
    Breast Cancer. 2021 Mar 15. pii: 10.1007/s12282-021-01237.
    PubMed         Abstract available
    
    
18. SASADA S, Masumoto N, Emi A, Kadoya T, et al
    Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis.
    Breast Cancer. 2021 Mar 19. pii: 10.1007/s12282-021-01236.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

19. SHALABI MG, Abbas AM, Mills J, Kheirelseid MA, et al
    The Prognostic Value of Estrogen Receptor beta Isoform With Correlation of Estrogen Receptor alpha Among Sudanese Breast Cancer Patients.
    Breast Cancer (Auckl). 2021;15:1178223421998354.
    PubMed         Abstract available
    
    
20. EL-SHEIKH N, Mousa NO, Tawfeik AM, Saleh AM, et al
    Assessment of Human Papillomavirus Infection and Risk Factors in Egyptian Women With Breast Cancer.
    Breast Cancer (Auckl). 2021;15:1178223421996279.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

21. MACPHERSON IR, He Y, Palmieri C
    Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
    Breast Cancer Res. 2021;23:33.
    PubMed         Abstract available
    
    
22. GRAESER M, Schrading S, Gluz O, Strobel K, et al
    Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
    Breast Cancer Res. 2021;23:36.
    PubMed         Abstract available
    
    
23. WU SY, Sharma S, Wu K, Tyagi A, et al
    Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
    Breast Cancer Res. 2021;23:35.
    PubMed         Abstract available
    
    
24. FIGUEROA JD, Gierach GL, Duggan MA, Fan S, et al
    Risk factors for breast cancer development by tumor characteristics among women with benign breast disease.
    Breast Cancer Res. 2021;23:34.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

25. HETTERICH M, Gerken M, Ortmann O, Inwald EC, et al
    Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
    Breast Cancer Res Treat. 2021 Mar 15. pii: 10.1007/s10549-021-06162.
    PubMed         Abstract available
    
    
26. GHARZAI LA, Szczygiel LA, Shumway DA, Bandos H, et al
    A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06172.
    PubMed         Abstract available
    
    
27. WU ZY, Han HH, Kim HJ, Lee JW, et al
    A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06114.
    PubMed         Abstract available
    
    
28. TOKUDA Y, Yanagawa M, Fujita Y, Honma K, et al
    Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06179.
    PubMed         Abstract available
    
    
29. IM YH, Karabulut B, Lee KS, Park BW, et al
    Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06173.
    PubMed         Abstract available
    
    
30. LLOYD KE, Hall LH, Ziegler L, Smith SG, et al
    Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06183.
    PubMed         Abstract available
    
    
31. WALSTRA CJEF, Schipper RJ, van Riet YE, van der Toorn PG, et al
    Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.
    Breast Cancer Res Treat. 2021 Mar 13. pii: 10.1007/s10549-021-06154.
    PubMed         Abstract available
    
    
32. SURETTE A, Yoo BH, Younis T, Matheson K, et al
    Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06164.
    PubMed         Abstract available
    
    

    
    Breast J

33. ANDERSON JD, Hammond JB, Kosiorek HE, Thorpe CS, et al
    Unplanned implant removal in locally advanced breast cancer.
    Breast J. 2021 Mar 14. doi: 10.1111/tbj.14224.
    PubMed         Abstract available
    
    
34. SILIQUINI GP, Bounous VE, Novara L, Giorgi M, et al
    Fractional CO(2) vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors.
    Breast J. 2021 Mar 16. doi: 10.1111/tbj.14211.
    PubMed         Abstract available
    
    
35. WEISS A, Cooley V, Al-Hilli Z, Ballman K, et al
    Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers.
    Breast J. 2021 Mar 15. doi: 10.1111/tbj.14226.
    PubMed         Abstract available
    
    
36. MA SJ, Yu B, Oladeru OT, Bartl AJ, et al
    Evaluation of adjuvant radiation and endocrine therapy in elderly patients with early-stage breast cancer.
    Breast J. 2021 Mar 15. doi: 10.1111/tbj.14228.
    PubMed        
    
    
37. LEHRBERG A, Davis MB, Baidoun F, Petersen L, et al
    Outcome of African-American compared to White-American patients with early-stage breast cancer, stratified by phenotype.
    Breast J. 2021 Mar 18. doi: 10.1111/tbj.14225.
    PubMed         Abstract available
    
    

    
    Cancer

38. TAMIRISA N, Lin H, Shen Y, Shaitelman SF, et al
    Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis.
    Cancer. 2021 Mar 18. doi: 10.1002/cncr.33489.
    PubMed         Abstract available
    
    

    
    Cancer Cell

39. LIANG H
    Size matters: toward reliable breast cancer risk assessment for every woman.
    Cancer Cell. 2021 Mar 8. pii: S1535-6108(21)00120.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

40. TURIJAN-ESPINOZA E, Ruiz-Rodriguez VM, Uresti-Rivera EE, Martinez-Leija E, et al
    Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
    Cancer Chemother Pharmacol. 2021 Mar 19. pii: 10.1007/s00280-021-04244.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

41. BRUINSMA TJ, Dyer AM, Rogers CJ, Schmitz KH, et al
    Effects of Diet and Exercise induced Weight Loss on Biomarkers of Inflammation in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
    Cancer Epidemiol Biomarkers Prev. 2021 Mar 18. pii: 1055-9965.EPI-20-1029.
    PubMed         Abstract available
    
    
42. GONZALO-ENCABO P, McNeil J, Perez-Lopez A, Valades D, et al
    Weight regain and breast cancer-related biomarkers following an exercise intervention in postmenopausal women.
    Cancer Epidemiol Biomarkers Prev. 2021 Mar 18. pii: 1055-9965.EPI-20-1652.
    PubMed         Abstract available
    
    

    
    Cancer Res

43. HU L, Su L, Cheng H, Mo C, et al
    Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.
    Cancer Res. 2021 Mar 16. pii: 0008-5472.CAN-20-2123.
    PubMed         Abstract available
    
    
44. CARVAJAL-MALDONADO D, Wood RD
    Regulating Poltheta in Breast Cancer.
    Cancer Res. 2021;81:1441-1442.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

45. BOUZIDI L, Triki H, Charfi S, Kridis WB, et al
    Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues.
    Clin Breast Cancer. 2021 Feb 16. pii: S1526-8209(21)00045.
    PubMed         Abstract available
    
    
46. GURU SD, Hoskin TL, Whaley DH, Nathan MA, et al
    Repeat Sentinel Lymph Node Surgery in Recurrent Breast Cancer: Peritumoral vs. Periareolar Injections.
    Clin Breast Cancer. 2021 Feb 18. pii: S1526-8209(21)00046.
    PubMed         Abstract available
    
    
47. LEE SJ, Lee J, Jung JH, Park HY, et al
    Exosomal Del-1 as a Potent Diagnostic Marker for Breast Cancer: Prospective Cohort Study.
    Clin Breast Cancer. 2021 Feb 17. pii: S1526-8209(21)00044.
    PubMed         Abstract available
    
    
48. SHARMA RD, Sharmin A, Sinha A, Solomon A, et al
    Is it Possible to Predict Non Sentinel Node Positivity on the Basis of mRNA Copy Numbers of CK19 Receptor in Breast Cancer?
    Clin Breast Cancer. 2021 Jan 23. pii: S1526-8209(21)00024.
    PubMed         Abstract available
    
    
49. WEI G, Kumar A, Lee MC, Wang X, et al
    Influential Factors on Risk-reduction Mastectomy in a High-risk Breast Cancer Population With Genetic Predispositions.
    Clin Breast Cancer. 2021 Jan 19. pii: S1526-8209(21)00020.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

50. BARDIA A, Hurvitz SA, DeMichele A, Clark AS, et al
    Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1).
    Clin Cancer Res. 2021 Mar 15. pii: 1078-0432.CCR-20-2114.
    PubMed         Abstract available
    
    
51. TOLANEY SM, Kalinsky K, Kaklamani V, D'Adamo DR, et al
    Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study.
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-20-4726.
    PubMed         Abstract available
    
    

    
    Eur Radiol

52. RAGUSI MAA, Loo CE, van der Velden BHM, Wesseling J, et al
    Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.
    Eur Radiol. 2020;30:6740-6748.
    PubMed         Abstract available
    
    

    
    Histopathology

53. THIKE AA, Chen X, Koh VCY, Binte Md Nasir ND, et al
    Higher densities of tumour-infiltrating lymphocytes and CD4(+) T cells predict recurrence and progression of ductal carcinoma in situ of the breast.
    Histopathology. 2020;76:852-864.
    PubMed         Abstract available
    
    
54. PAREJA F, Toss MS, Geyer FC, da Silva EM, et al
    Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
    Histopathology. 2020;76:865-874.
    PubMed         Abstract available
    
    

    
    Int J Cancer

55. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed         Abstract available
    
    
56. KOCH T, Jorgensen JT, Christensen J, Dehlendorff C, et al
    Breast Cancer Rate after Oophorectomy: A Prospective Danish Cohort Study.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33563.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

57. VAN DEN BOGAARD VAB, Spoor DS, van der Schaaf A, van Dijk LV, et al
    The Importance of Radiation Dose to the Atherosclerotic Plaque in the Left Anterior Descending Coronary Artery for Radiation-Induced Cardiac Toxicity of Breast Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Mar 10. pii: S0360-3016(21)00244.
    PubMed         Abstract available
    
    
58. BELLON JR, Chen YH, Rees R, Taghian AG, et al
    A phase I dose-escalation trial of radiation therapy and concurrent cisplatin for stage II and III triple-negative breast cancer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 10. pii: S0360-3016(21)00242.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

59. VERDIAL FC, Bartek MA, Anderson BO, Javid SH, et al
    Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort.
    J Surg Oncol. 2021 Mar 18. doi: 10.1002/jso.26372.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

60. PICCART M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, et al
    70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Lancet Oncol. 2021 Mar 12. pii: S1470-2045(21)00007.
    PubMed         Abstract available
    
    

    
    Nature

61. QUINTON RJ, DiDomizio A, Vittoria MA, Kotynkova K, et al
    Whole-genome doubling confers unique genetic vulnerabilities on tumour cells.
    Nature. 2021;590:492-497.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

62. STEENBRUGGE J, Vander Elst N, Demeyere K, De Wever O, et al
    OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer.
    NPJ Breast Cancer. 2021;7:27.
    PubMed         Abstract available
    
    

    
    Oncogene

63. MARTINEZ-ORDONEZ A, Seoane S, Avila L, Eiro N, et al
    POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01740.
    PubMed         Abstract available
    
    
64. CHEN T, Wang X, Li C, Zhang H, et al
    CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01739.
    PubMed         Abstract available
    
    

    
    Oncology

65. MONTAGNA G, Tong Y, Ritter M, Levi J, et al
    Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.
    Oncology. 2021 Mar 18:1-6. doi: 10.1159/000513454.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

66. CLIMENTE-GONZALEZ H, Lonjou C, Lesueur F, Stoppa-Lyonnet D, et al
    Boosting GWAS using biological networks: A study on susceptibility to familial breast cancer.
    PLoS Comput Biol. 2021;17:e1008819.
    PubMed         Abstract available
    
    

    
    PLoS One

67. RAHIMZADEH S, Burczynska B, Ahmadvand A, Sheidaei A, et al
    Geographical and socioeconomic inequalities in female breast cancer incidence and mortality in Iran: A Bayesian spatial analysis of registry data.
    PLoS One. 2021;16:e0248723.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

68. YAMAZAKI H, Suzuki G, Takenaka T, Aibe N, et al
    Objective and quantitative assessment in acute radiation-induced skin toxicity: Way to overcome the barriers?
    Radiother Oncol. 2020;151:304-305.
    PubMed        
    
    
69. FERNANDO IN, Lax S, Ahmed I
    Response to Gultekin et al. regarding SECRAB trial toxicity.
    Radiother Oncol. 2020;147:233.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: